Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) P/B ratio
As of 5 November 2026, Medpace Holdings, Inc. (MEDP) trades at a P/B ratio of 30.3×. Over the past ten years it has ranged from 1.5× (May 2017) to 83.3× (September 2025); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 35.3× | 183.28% |
| FY2024 | 12.5× | (25.83%) |
| FY2023 | 16.8× | (3.79%) |
| FY2022 | 17.5× | 113.15% |
| FY2021 | 8.2× | 33.05% |
| FY2020 | 6.2× | 48.23% |
| FY2019 | 4.2× | 30.16% |
| FY2018 | 3.2× | 10.76% |
| FY2017 | 2.9× | 37.27% |
| FY2016 | 2.1× | (6.99%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 29.8× | (13.31%) |
| Jun 2026 | 34.4× | 50.64% |
| Mar 2026 | 22.8× | (35.31%) |
| Dec 2025 | 35.3× | (28.36%) |
| 40 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| ICLR ICON PLC compare | 1.7× |
| RVTY Revvity Inc. compare | 2.3× |
| QGEN QIAGEN N.V. compare | 3.1× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| CRL Charles River Laboratories International, Inc. compare | 4.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| MEDP Medpace Holdings, Inc. | 30.3× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement